Literature DB >> 24707835

MicroRNAs in gastrointestinal cancer: prognostic significance and potential role in chemoresistance.

Liu Hong1, Yu Han, Jianjun Yang, Hongwei Zhang, Qingchuan Zhao, Kaichun Wu, Daiming Fan.   

Abstract

INTRODUCTION: Although chemotherapy is an important therapeutic strategy for gastrointestinal cancer, its clinical effect remains unsatisfied due to drug resistance. Drug resistance is a complex multistep process resulting from deregulated expression of many molecules, including tumor suppressor genes, oncogenes and microRNAs (miRNAs). A better understanding of drug resistance-related miRNAs may eventually lead to optimized therapeutic strategies for cancer patients. AREAS COVERED: This review summarizes the recent advances of drug resistance-related miRNAs in esophageal, gastric and colorectal cancer. Furthermore, this study envisages future developments toward the clinical applications of these miRNAs to cancer therapy. EXPERT OPINION: Drug resistance-related miRNAs may be potentially predicting biomarkers that help guide individualized chemotherapy. Specific miRNAs and their target genes can be used as therapeutic targets by reversing drug resistance. More investigations should be performed to promote the translational bridging of the latest research into clinical application.

Entities:  

Keywords:  colon cancer; drug resistance; esophageal cancer; gastric cancer; microRNA; rectal cancer

Mesh:

Substances:

Year:  2014        PMID: 24707835     DOI: 10.1517/14712598.2014.907787

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  9 in total

1.  Downregulation of rho-associated protein kinase 1 by miR-124 in colorectal cancer.

Authors:  Zuo-Wu Xi; Shi-Yong Xin; Li-Qing Zhou; Hai-Xin Yuan; Qian Wang; Kai-Xuan Chen
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 2.  Gastrointestinal cancer drug resistance: the role of exosomal miRNAs.

Authors:  Mahsa Salehi; Asma Vafadar; Seyyed Hossein Khatami; Mortaza Taheri-Anganeh; Omid Vakili; Amir Savardashtaki; Babak Negahdari; Parisa Naeli; Hamid Behrouj; Hassan Ghasemi; Ahmad Movahedpour
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

Review 3.  MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer.

Authors:  Jian Wang; Yong Du; Xiaoming Liu; William C Cho; Yinxue Yang
Journal:  Biomed Res Int       Date:  2015-05-06       Impact factor: 3.411

4.  Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.

Authors:  Edita Baltruskeviciene; Diana Schveigert; Vaidotas Stankevicius; Ugnius Mickys; Tadas Zvirblis; Jaroslav Bublevic; Kestutis Suziedelis; Eduardas Aleknavicius
Journal:  BMC Cancer       Date:  2017-09-01       Impact factor: 4.430

5.  Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection.

Authors:  Xiaohong Wang; Yiqiang Liu; Zhaojian Niu; Runjia Fu; Yongning Jia; Li Zhang; Duanfang Shao; Hong Du; Ying Hu; Xiaofang Xing; Xiaojing Cheng; Lin Li; Ting Guo; Ziyu Li; Qunsheng Ji; Lianhai Zhang; Jiafu Ji
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

6.  MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer.

Authors:  Wen-Cui Li; Yan-Qiong Wu; Bo Gao; Chao-Yun Wang; Juan-Juan Zhang
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

7.  Prognostic significance of cystatin SN associated nomograms in patients with colorectal cancer.

Authors:  Taiyuan Li; Qiangqiang Xiong; Zhen Zou; Xiong Lei; Qunguang Jiang; Dongning Liu
Journal:  Oncotarget       Date:  2017-12-08

8.  miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1.

Authors:  Wei Lu; Yunping Hu; Qiang Ma; Linzhu Zhou; Lin Jiang; Zhizhen Li; Shuai Zhao; Yuzhen Xu; Weibin Shi; Sheng Li; Yingbin Liu
Journal:  Oncotarget       Date:  2016-09-20

9.  miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer.

Authors:  Marc Campayo; Alfons Navarro; Jose Carlos Benítez; Sandra Santasusagna; Carme Ferrer; Mariano Monzó; Luis Cirera
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.